Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studiesInfectious Diseases Published on 2024-08-192024-09-05 Journal: Annals of Medicine [Category] update2024, [키워드] adverse events COVID-19 vaccination influenza vaccination neutralizing antibody seroconversion rate systemic lupus erythematosus [DOI] 10.1080/07853890.2024.2392882 PMC 바로가기 [Article Type] Infectious Diseases
Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cureOriginal Article Published on 2023-11-272024-09-05 Journal: The Brazilian Journal of Infectious Diseases [Category] update2024, [키워드] Anti-HBs functional cure HBsAg seroclearance hepatitis B IFNα therapy seroconversion rate vaccination [DOI] 10.1016/j.bjid.2023.103703 PMC 바로가기 [Article Type] Original Article
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2Review Published on 2023-03-282024-09-04 Journal: Blood reviews [Category] 대상포진, [키워드] cellular immunity hematological diseases SARS-CoV-2 seroconversion rate vaccination [DOI] 10.1016/j.blre.2023.101077 PMC 바로가기 [Article Type] Review
SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine RolloutArticle Published on 2023-03-042024-09-05 Journal: Biological Research for Nursing [Category] update2024, [키워드] exposure risk healthcare worker infection rate SARS-CoV-2 seroconversion rate [DOI] 10.1177/10998004231161632 PMC 바로가기 [Article Type] Article
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age Analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control studyArticle Published on 2022-11-302022-11-15 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-SARS-CoV-2 antibodies antibody Antibody Response Case-control case-control study China confidence interval Control COVID-19 infection COVID-19 pandemic Department dose Hospitalization hospitalized patient inactivated lack management Odds ratio participant Participants Protective SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine seroconversion rate seronegative seronegative participant seropositive participant Sex Sinopharm tested the antibody response the SARS-CoV-2 the vaccine Urology vaccination Vaccine was obtained were assessed [DOI] 10.1080/21645515.2022.2088966 PMC 바로가기
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)Article Published on 2022-11-012022-11-15 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-RBD antibody B cell response BNT162b2 booster Cell-mediated immunity ChAdOx1 ChAdOx1 nCoV-19 comparable Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose elicit group humoral immunization Immunocompromised immunogenicity investigated IQR kidney transplant male median mononuclear cells mRNA mRNA-1273 no difference participant Peripheral blood positive Randomized Randomized controlled trial receive recipients response SARS-CoV-2 seroconversion rate significantly statistically T cell Vaccine Viral vector virus neutralization test [DOI] 10.1111/ajt.17151 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
Longitudinal survey of humoral and cellular response to SARS-CoV-2 infection in childrenArticle Published on 2022-11-012022-11-15 Journal: Microbiological research [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Abbott acute infection age analysed anti-RBD IgG antibody antibody blood sample cellular response children COVID-19 decrease diagnosed humoral Humoral response IgG IgG antibodies IgG antibody IgG response immune response Infection longitudinal longitudinal study molecular nasopharyngeal swabs Oxford paediatric patient participant Patient persistence positive SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection seroconversion rate seroconverted seropositive significant decrease suffered T-cell Response [DOI] 10.1016/j.micres.2022.127145 PMC 바로가기